ArticleFrontiers in medicine2021
Oral Scutellarin Treatment Ameliorates Retinal Thinning and Visual Deficits in Experimental Glaucoma.
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Dual-functional nanoparticle formulations for simultaneous intraocular pressure reduction and neuroprotection in glaucoma: a review.Nanomedicine (London, England) · 2026Review
- Scutellarin Protects Retinal Ganglion Cells in Glaucoma by Targeting the Hsp90aa1-MAPK Pathway to Inhibit Apoptosis.Investigative ophthalmology & visual science · 2025Article
- Testing Visual Function by Assessment of the Optomotor Reflex in Glaucoma.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Article
- Current advances on the therapeutic potential of scutellarin: an updated review.Natural products and bioprospecting · 2024Review
- Early inner plexiform layer thinning and retinal nerve fiber layer thickening in excitotoxic retinal injury using deep learning-assisted optical coherence tomography.Acta neuropathologica communications · 2024Article
- Ocular manifestations of central insulin resistance.Neural regeneration research · 2023Article
- Reverse translation of artificial intelligence in glaucoma: Connecting basic science with clinical applications.Frontiers in ophthalmology · 2023Article
- Effects of scutellarin on the mechanism of cardiovascular diseases: a review.Frontiers in pharmacology · 2023Review
- Based on multiple machine learning to identify the ENO2 as diagnosis biomarkers of glaucoma.BMC ophthalmology · 2022Article
- Treatment of Glaucoma with Natural Products and Their Mechanism of Action: An Update.Nutrients · 2022Review
- Diffusion Tensor Imaging of Visual Pathway Abnormalities in Five Glaucoma Animal Models.Investigative ophthalmology & visual science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 4 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.